0001415889-24-019383.txt : 20240708
0001415889-24-019383.hdr.sgml : 20240708
20240708185504
ACCESSION NUMBER: 0001415889-24-019383
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240703
FILED AS OF DATE: 20240708
DATE AS OF CHANGE: 20240708
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Milnes Alistair
CENTRAL INDEX KEY: 0001901321
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 241106054
MAIL ADDRESS:
STREET 1: C/O BICYCLE THERAPEUTICS PLC
STREET 2: B900, BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS PLC
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BLOCKS A & B, PORTWAY BUILDING
STREET 2: GRANTA PARK, GREAT ABINGTON
CITY: CAMBRIDGE
STATE: X0
ZIP: CB21 6GS
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: BLOCKS A & B, PORTWAY BUILDING
STREET 2: GRANTA PARK, GREAT ABINGTON
CITY: CAMBRIDGE
STATE: X0
ZIP: CB21 6GS
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS plc
DATE OF NAME CHANGE: 20190530
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
form4-07082024_060701.xml
X0508
4
2024-07-03
0001761612
BICYCLE THERAPEUTICS PLC
BCYC
0001901321
Milnes Alistair
C/O BICYCLE THERAPEUTICS PLC
BLOCKS A & B, PORTWAY BUILDING
CAMBRIDGE
X0
CB21 6GS
UNITED KINGDOM
false
true
false
false
CHIEF OPERATING OFFICER
0
Ordinary Shares
2024-07-03
4
S
0
967
19.64
D
71274
D
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Laura Berezin, Attorney-in-Fact
2024-07-08